|
Cyterix Pharmaceuticals Raises $9.2 Million in a Series A Venture Financing
SV Life Sciences is a venture capital fund providing financing to businesses at all stages of development across the human life sciences sector, including biotechnology, pharmaceuticals, medical devices and instruments, and healthcare. Cyterix is developing novel cancer therapeutics based on a prodrug approach that targets extra-hepatic cytochrome P450 enzymes that are over-expressed in many cancers to a high frequency, but not in normal tissues. The company’s goal is to discover and develop multiple classes of small molecule oncology prodrugs with a superior safety and efficacy profile to classical cytotoxic and molecularly targeted agents.
read more...
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
New Life Sciences Company to Establish Headquarters in Indiana
BioCritica, a newly formed biotechnology company, will establish its headquarters in Central Indiana, creating up to 70 new jobs by 2015. Recently founded by Eli Lilly and Company and a private investor group, BioCritica will develop, market and commercialize products for the critical care hospital market.
read more...
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
FDA Approves Trial of Pathway Therapeutics, Inc. Cancer Drug
Pathway Therapeutics, Inc., a company developing novel therapeutics that target the PI3K and mTOR pathways, today announced that the FDA has accepted an IND filing for PWT33597, which allows Pathway to commence Phase 1 clinical testing.
read more...
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
|
